 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH, a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation ORACLE study, a 1,000-patient prospective, observational, multi-center study designed to evaluate the performance of its Guardant RevealTM liquid biopsy test to predict cancer recurrence after curative intent treatment, across 11 solid tumor types. For oncologists managing patients with early-stage cance 